This is partly consistent with results from other studies examining DAs for women with pathogenic BRCA1 and BRCA2 variants: DA use either had no effect on anxiety [39], lowered cancer-related distress [38], or was associated with a temporarily short-term increase in distress [51] in the first month after DA use that subsequently decreased. This evidence concerns the gene BRCA2 and Anxiety.